Selected article for: "acid protease and acute respiratory"
Author: Pitt, Bertram; Sutton, Nadia R.; Wang, Zhong; Goonewardena, Sascha N.; Holinstat, Michael
Title: Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19
  • Cord-id: f98yr4iu
  • Document date: 2021_5_5
    • ID: f98yr4iu
    Snippet: There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This article will review the reasons to consider valproic acid as a potential therapeutic to prevent severe COVID-19. Valproic ac
    Document: There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This article will review the reasons to consider valproic acid as a potential therapeutic to prevent severe COVID-19. Valproic acid could reduce angiotensin-converting enzyme 2 and transmembrane serine protease 2 expression, required for SARS-CoV-2 viral entry, and modulate the immune cellular and cytokine response to infection, thereby reducing end-organ damage. The combined anti-thrombotic, anti-platelet, and anti-inflammatory effects of valproic acid suggest it could be a promising therapeutic target for COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abundant evidence and acute respiratory syndrome: 1
    • acid effect and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acid effect and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acid effect and adaptive innate: 1
    • acid effect and lps lipopolysaccharide: 1, 2, 3, 4
    • acid valproic and acute ards respiratory distress syndrome: 1, 2
    • acid valproic and acute renal failure: 1
    • acid valproic and acute respiratory: 1, 2, 3, 4, 5, 6, 7
    • acid valproic and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • acid valproic and lps lipopolysaccharide: 1